Liyi Li

Dr. Liyi Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
XLXin Liu
Xin Liu
JZJinwei Zhu
Jinwei Zhu
CLChen Li
Chen Li
CTChen Tong
Chen Tong
CZCong Zhao
Cong Zhao
LLLiyi Li
Liyi Li

18 October 2025 in Cellular Signalling
Verified
Journal Article
Closed access
YLYue Luo
Yue Luo
YXYishan Xu
Yishan Xu
XCXi Chen
Xi Chen
SWShitong Wang
Shitong Wang
XLXinheng Liu
Xinheng Liu
LLLiyi Li
Liyi Li

26 June 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
CZCe Zhu
Ce Zhu
CMChenchen Mao
Chenchen Mao
WCWentao Cai
Wentao Cai
JZJingwei Zheng
Jingwei Zheng
HYHui Yang
Hui Yang
LLLiyi Li
Liyi Li
Background: Metabolic syndrome (MetS) is associated with poor prognosis in many cancers. However, the relationship between metabolic syndrome and overall survival (OS) in patients with colorectal cancer (CRC) remains unclear. We aimed to comprehensively analyze whether MetS could affect postoperative complications and long-term survival in patients with CRC.Methods: We included patients who underwent CRC resection at our center between January 2016 and December 2018. Bias was reduced through propensity score matching analysis. Patients with CRC were divided into the MetS and non-MetS groups based on whether they had MetS. Univariate and multivariate analyses were used to identify risk factors affecting OS.Results: We included 268 patients; among them, 120 were included for further analysis after propensity score matching. There were no significant between-group differences in the clinicopathological features after matching. Compared with the non-MetS group, the MetS group had a shorter OS (P = 0.027); however, there was no significant between-group difference in postoperative complications. Multivariate analysis revealed that MetS (hazard ratio [HR] = 1.997, P = 0.042), tumor-node-metastasis stage (HR = 2.422, P = 0.003), and intestinal obstruction (HR = 2.761, P = 0.010) were independent risk factors for OS.Conclusions: MetS affects the long-term survival of patients with CRC without affecting postoperative complications.

11 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
CZCe Zhu
Ce Zhu
WCWentao Cai
Wentao Cai
JZJingwei Zheng
Jingwei Zheng
HYHui Yang
Hui Yang
TYTao You
Tao You
LLLiyi Li
Liyi Li
Purpose: Metabolic syndrome (MetS) is associated with poor prognosis in many cancers. However, few studies have comprehensively analyzed the relationship between metabolic syndrome and the overall survival of colorectal cancer (CRC) patients. Our study aimed to comprehensively analyze whether MetS could affect postoperative complications and long-term survival in patients with CRC.Patients and methods: We included patients who underwent colorectal cancer resection at our center between January 2016 and December 2018 for this analysis. The propensity score matching analysis was performed to reduce the bias. Dividing CRC patients into MetS and Non-MetS groups based on whether they had MetS. Univariate and multivariate analyses were used to identify the risk factors affecting overall survival (OS).Results: A total of 268 patients were included in the study, of whom 120 patients were included for further analysis after propensity score matching. No significant differences were found in Clinicopathological features between the MetS group and Non-MetS group after matching. Patients with MetS had a shorter OS compared with non-MetS (P=0.027), however the postoperative complications were not significantly different between them. In multivariate analysis, We found MetS (hazard ratio [HR]=1.997, P=0.042), tumor-node-metastasis (TNM) stage (HR=2.422, P=0.003), and intestinal obstruction (HR=2.761, P=0.010) were independent risk factors for OS. Conclusion: Metabolic syndrome affects long-term survival of CRC patients without affecting postoperative complications.